Skip Navigation

Phase III Trial of Neoadjuvant Durvalumab NSC 778709 plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh MP2 Hormone Receptor HR Positive / Human Epidermal Growth Factor Receptor HER2 Negative Stage II-III Breast Cancer

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06058377

Study #:
STUDY00160151

Start Date:
Apr 02, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06058377

View Complete Trial Details & Eligibility at ClinicalTrials.gov